Chemically-sensitive field effect transistor

Information

  • Patent Grant
  • 10429342
  • Patent Number
    10,429,342
  • Date Filed
    Wednesday, December 9, 2015
    9 years ago
  • Date Issued
    Tuesday, October 1, 2019
    5 years ago
Abstract
A chemically-sensitive field effect transistor is disclosed herein. The chemically-sensitive field effect transistor comprises a CMOS structure comprising a conductive source and a conductive drain, a channel and an analyte-sensitive dielectric layer. The channel extends from the conductive source to the conductive drain. The channel is composed of a one-dimensional transistor material or a two-dimensional transistor material. The analyte-sensitive dielectric layer is disposed over the channel. An I-V curve or an I-Vg curve is shifted in response to a chemical reaction occurring on or near the chemically-sensitive field effect transistor.
Description
STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT

Not Applicable


BACKGROUND OF THE INVENTION
Field of the Invention

The present invention generally relates to field effect transistors. More specifically, the present invention relates to one dimensional and two dimensional field effect transistors.


Description of the Related Art

The sequencing of Nucleic Acids, such as deoxyribonucleic acid (DNA), is a fundamental part of biological discovery. Such detection is useful for a variety of purposes and is often used in scientific research as well as medical advancement. For instance, the genomics and bioinformatics fields are concerned with the application of information technology and computer science to the field of molecular biology. In particular, bioinformatics techniques can be applied to process and analyze various genomic data, such as from an individual so as to determine qualitative and quantitative information about that data that can then be used by various practitioners in the development of diagnostic, prophylactic, and/or therapeutic methods for detecting, preventing or at least ameliorating diseased states, and thus, improving the safety, quality, and effectiveness of health care. The need for such diagnostic, therapeutic, and prophylactic advancements has led to a high demand for low-cost sequencing, which in turn has driven the development of high-throughput sequencing, termed as Next generation sequencing (NGS).


Generally, the approach to DNA analysis, such as for genetic diagnostics and/or sequencing, involves nucleic acid hybridization and detection. For example, various typical hybridization and detection approaches include the following steps. For genetic analysis, an RNA or DNA sample of a subject to be analyzed may be isolated and immobilized on a substrate, a probe of a known genetic sequence, e.g., a disease marker, may be labeled and washed across the substrate. If the disease marker is present, a binding event will occur, e.g., hybridization, and because the probe has been labeled the hybridization event may either be or not be detected thereby indicating the presence or absence of the disease marker in the subject's sample.


For DNA sequencing, first, an unknown nucleic acid sequence to be identified, e.g., a single-stranded sequence of DNA of a subject, is isolated, amplified, and immobilized on a substrate. Next, a known nucleic acid labeled with an identifiable tag is contacted with the unknown nucleic acid sequence in the presence of a polymerase. When hybridization occurs, the labeled nucleic acid binds to its complementary base in the unknown sequence immobilized on the surface of the substrate. The binding event can then be detected, e.g., optically or electrically. These steps are then repeated until the entire DNA sample has been completely sequenced. Typically, these steps are performed by a Next Gen Sequencer wherein thousands to millions of sequences may concurrently be produced in the next-generation sequencing process.


For example, a central challenge in DNA sequencing is assembling full-length genomic sequences, e.g., chromosomal sequences, from a sample of genetic material and/or mapping and aligning sample sequence fragments to a reference genome, yielding sequence data in a format that can be compared to a reference genomic sequence such as to determine the variants in the sampled full-length genomic sequences. In particular, the methods employed in sequencing protocols do not produce full-length chromosomal sequences of the sample DNA.


Rather, sequence fragments, typically from 100-1,000 nucleotides in length, are produced without any indication as to where in the genome they align. Therefore, in order to generate full length chromosomal genomic constructs, or determine variants with respect to a reference genomic sequence, these fragments of DNA sequences need to be mapped, aligned, merged, and/or compared to a reference genomic sequence. Through such processes the variants of the sample genomic sequences from the reference genomic sequences may be determined.


However, as the human genome is comprised of approximately 3.1 billion base pairs, and as each sequence fragment is typically only from 100 to 500 to 1,000 nucleotides in length, the time and effort that goes into building such full length genomic sequences and determining the variants therein is quite extensive often requiring the use of several different computer resources applying several different algorithms over prolonged periods of time.


In a particular instance, thousands to millions of fragments or even billions of DNA sequences are generated, aligned, and merged in order to construct a genomic sequence that approximates a chromosome in length. A step in this process may include comparing the DNA fragments to a reference sequence to determine where in the genome the fragments align.


The genetic material must be pre-processed, so as to derive usable genetic sequence data. This preprocessing may be done manually or via an automated sequencer. Typically, preprocessing involves obtaining a biological sample from a subject, such as through venipuncture, hair, etc. and treating the sample to isolate the DNA therefrom. Once isolated the DNA may be denatured, strand separated, and/or portions of the DNA may then be multiplied, e.g., via polymerase chain reaction (PCR), so as to build a library of replicated strands that are now ready to be read, such as by an automated sequencer, which sequencer is configured to read the replicate strands, e.g., by synthesis, and thereby determine the nucleotide sequences that makes up the DNA. Further, in various instances, such as in building the library of replicated strands, it may be useful to provide for over-coverage when preprocessing a given portion of the DNA. To perform this over-coverage, e.g., using PCR, may require increased sample preparation resources and time, and therefore be more expensive, but it often gives an enhanced probability of the end result being more accurate.


Once the library of replicated strands has been generated they may be injected into an automated sequencer that may then read the strands, such as by synthesis, so as to determine the nucleotide sequences thereof. For instance, the replicated single stranded DNA may be attached to a glass bead and inserted into a test vessel, e.g., an array. All the necessary components for replicating its complementary strand, including labeled nucleotides, are also added to the vessel but in a sequential fashion. For example, all labeled “A”, “C”, “G”, and “T's” are added, either one at a time or all together to see which of the nucleotides is going to bind at position one. After each addition a light, e.g., a laser, is shone on the array. If the composition fluoresces then an image is produced indicating which nucleotide bound to the subject location. More particularly, where the nucleotides are added one at a time, if a binding event occurs, then its indicative fluorescence will be observed. If a binding event does not occur, the test vessel may be washed and the procedure repeated until the appropriate one of the four nucleotides binds to its complement at the subject location, and its indicative fluorescence is observed. Where all four nucleotides are added at the same time, each may be labeled with a different fluorescent indicator, and the nucleotide that binds to its complement at the subject position may be determined, such as by the color of its fluorescence. This greatly accelerates the synthesis process.


Once a binding event has occurred, the complex is then washed and the synthesis steps are repeated for position two. For example, a marked nucleotide “A” may be added to the mix to determine if the complement at the position is a “T”, and if so, all the sequences having that complement will bind to the labeled “T” and will therefore fluoresce, and the samples will all be washed. Where the binding happened the bound nucleotide is not washed away, and then this will be repeated for all nucleotides for all positions until all the over-sampled nucleic acid segments, e.g., reads, have been sequenced and the data collected. Alternatively, where all four nucleotides are added at the same time, each labeled with a different fluorescent indicator, only one nucleotide will bind to its complement at the subject position, and the others will be washed away, such that after the vessel has been washed, a laser may be shone on the vessel and which nucleotide bound to its complement may be determined, such as by the color of its fluorescence.


This continues until the entire strand has been replicated in the vessel. Usually a typical length of a sequence replicated in this manner is from about 100 to about 500 base pairs, such as between 150 to about 400 base pairs, including from about 200 to about 350 base pairs, such as about 250 base pairs to about 300 base pairs dependent on the sequencing protocol being employed. Further, the length of these segments may be predetermined, e.g., engineered, to accord with any particular sequencing machinery and/or protocol by which it is run. The end result is a readout, or read, that is comprised of a replicated DNA segment, e.g., from about 100 to about 1,000 nucleotides in length, that has been labeled in such a manner that every nucleotide in the sequence, e.g., read, is known because of its label. Hence, since the human genome is comprised of about 3.2 billion base pairs, and various known sequencing protocols usually result in labeled replicated sequences, e.g., reads, from about 100 or 101 bases to about 250 or about 300 or about 400 bases, the total amount of segments that need to be sequenced, and consequently the total number of reads generated, can be anywhere from about 10,000,000 to about 40,000,000, such as about 15,000,000 to about 30,000,000, dependent on how long the label replicated sequences are. Therefore, the sequencer may typically generate about 30,000,000 reads, such as where the read length is 100 nucleotides in length, so as to cover the genome once.


However, in part, due to the need for the use of optically detectable, e.g., fluorescent, labels in the sequencing reactions being performed, the required instrumentation for performing such high throughput sequencing is bulky, costly, and not portable. For this reason, a number of new approaches for direct, label-free detection of DNA sequencing have been proposed. For instance, among the new approaches are detection methods that are based on the use of various electronic analytic devices. Such direct electronic detection methods have several advantages over the typical NGS platform. For example, the detector may be incorporated in the substrate itself, such as employing a biosystem-on-a-chip device, such as a complementary metal oxide semiconductor device, “CMOS”. More particularly, in using a CMOS device in genetic detection, the output signal representative of a hybridization event can be directly acquired and processed on a microchip. In such an instance, automatic recognition is achievable in real time and at a lower cost than is currently achievable using NGS processing. Moreover, standard CMOS devices may be employed for such electronic detection making the process simple, inexpensive, and portable.


Particularly, in order for next-generation sequencing to become widely used as a diagnostic in the healthcare industry, sequencing instrumentation will need to be mass produced with a high degree of quality and economy. One way to achieve this is to recast DNA sequencing in a format that fully leverages the manufacturing base created for computer chips, such as complementary metal-oxide semiconductor (CMOS) chip fabrication, which is the current pinnacle of large scale, high quality, low-cost manufacturing of high technology. To achieve this, ideally the entire sensory apparatus of the sequencer could be embodied in a standard semiconductor chip, manufactured in the same fab facilities used for logic and memory chips. Recently, such a sequencing chip, and the associated sequencing platform, has been developed and commercialized by Ion Torrent, a division of Thermo-Fisher, Inc. The promise of this idea has not been realized commercially due to the fundamental limits of applying a metal oxide semiconductor field effect transistor, or MOSFET, as a bio sensor. When a MOSFET is used in solution as a biosensor, it is referred to as an ISFET. A particular limitation includes a lack of sensor sensitivity and signal to noise characteristics as the semiconductor node scales down to lower geometries of the transistor (gate length).


More particularly, a field effect transistor, FET, typically includes a gate, a channel region connecting source and drain electrodes, and an insulating barrier separating the gate from the channel. The operation of a conventional FET relies on the control of the channel conductivity, and thus the drain current, by a voltage, VGS, applied between the gate and source. For high-speed applications, and for the purposes of increasing sensor sensitivity, FETs should respond quickly to variations in VGS. However, this requires short gates and fast carriers in the channel. Unfortunately, FETs with short gates frequently suffer from degraded electrostatics and other problems (collectively known as short channel effects), such as threshold-voltage roll-off, drain-induced barrier lowering, and impaired drain-current saturation, which results in a decrease in sensor sensitivity. Nevertheless, scaling theory predicts that a FET with a thin barrier and a thin gate-controlled region (measured in the vertical direction) will be robust against short-channel effects down to very short gate lengths (measured in the horizontal direction).


Accordingly, the possibility of having channels that are very thin in the vertical dimension would allow for high-speed transmission of carriers as well as for increased sensor sensitivity and accuracy. What is needed, therefore, is a FET device that is configured in such a manner as to include a shorter gate than is currently achievable in present FET applications. A solution that includes such a FET device designed for use in biological applications, such as for nucleic acid sequencing and/or genetic diagnostics would especially be beneficial.


BRIEF SUMMARY OF THE INVENTION

The present invention is a chemically-sensitive field-effect transistor that solves many of the current problems associated with nucleic acid sequencing and genetic diagnostics.


One aspect of the present invention is a chemically-sensitive field effect transistor. The chemically-sensitive field effect transistor comprises an integrated circuit structure comprising a conductive source and a conductive drain and a channel. The channel extends from the conductive source to the conductive drain. The channel is composed of a one-dimensional transistor material or a two-dimensional transistor material. An I-V curve or an I-Vg curve is shifted in response to a chemical reaction occurring on or near the chemically-sensitive field effect transistor.


Another aspect of the present invention is a bio-sensor. The bio-sensor includes a semiconductor structure comprising a conductive source and a conductive drain, a 2D material channel (e.g. a graphene channel) or a 1D material channel (e.g. a Carbon NanoTube (CNT)) extending from the source to the drain and a well structure positioned on or over a portion of an exterior surface or topmost portion of the channel. The 1D or 2D material comprising the channel may be covered by a dielectric layer or may have no covering such that the well structure defines an opening allowing for direct contact with the either the dielectric layer or the 1D or 2D material channel. An I-Vg curve is shifted in response to detection of a biological compound.


Yet another aspect of the present invention is a 1D or 2D material field effect transistor such as a graphene field effect transistor or GFET. The GFET includes a structure comprising a conductive source, a conductive drain, and a graphene channel extending from the source to the drain. An I-Vg curve is shifted in response to a chemical reaction occurring on the graphene field effect transistor.


Yet another aspect of the present invention is a chemically-sensitive field effect transistor comprising an integrated circuit structure, a channel and an oxide layer. The integrated circuit structure comprises a conductive source and a conductive drain. The channel extends from the conductive source to the conductive drain. The channel is composed of a one-dimensional transistor material or a two-dimensional transistor material. The oxide layer is disposed over the channel. The I-V curve or an I-Vg curve is shifted in response to a chemical reaction occurring over or near the chemically-sensitive field effect transistor.


Yet another aspect of the present invention is a bio-sensor comprising a complementary metal-oxide-semiconductor (“CMOS”) structure, a graphene channel, an oxide layer, and a well structure. The CMOS structure comprises a damascene copper source and a damascene copper drain. The graphene channel extends from the source to the drain. The oxide layer is disposed over the graphene channel and has a thickness of 50 nanometers or less. The well structure is positioned over a portion of an exterior surface of the oxide layer. The well structure defines an opening allowing for direct contact with the oxide layer. An I-V or I-Vg curve is shifted in response to detection of a biological compound.


Yet another aspect of the present invention is a graphene field effect transistor comprising a CMOS structure, a graphene channel, an oxide layer, and a well structure. The CMOS structure comprises a copper source and a copper drain. The graphene channel extends from the source to the drain. The oxide layer is disposed over the graphene channel and has a thickness of 50 nanometers or less. The well structure is positioned over a portion of an exterior surface of the oxide layer. The well structure defines an opening allowing for direct contact with the oxide layer. An I-V or I-Vg curve is shifted in response to detection of a biological compound.


Having briefly described the present invention, the above and further objects, features and advantages thereof will be recognized by those skilled in the pertinent art from the following detailed description of the invention when taken in conjunction with the accompanying drawings.





BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWINGS


FIG. 1 is a cross-section diagram of a chemically-sensitive field-effect transistor utilized for analysis of biological or chemical materials.



FIG. 1A is a cross-section diagram of a chemically-sensitive field-effect transistor utilized for analysis of biological or chemical materials.



FIG. 2 is a cross-section diagram of a chemically-sensitive field-effect transistor with a well structure.



FIG. 2A is a cross-section diagram of a chemically-sensitive field-effect transistor with a well structure.



FIG. 3 is a cross-section diagram of a chemically-sensitive field-effect transistor.



FIG. 3A is a cross-section diagram of a chemically-sensitive field-effect transistor.



FIG. 4 is a top plan view of a chemically-sensitive field-effect transistor with a well structure.



FIG. 5 is a block diagram of a system for analysis of biological or chemical materials.



FIG. 6 is a top plan view of an array comprising multiple chemically-sensitive field-effect transistors.



FIG. 7 is an illustration of graphene.



FIG. 8 is a graph of average sensitivity of a graphene FET (“GFET”) calculated as a function of liquid gate potential.



FIG. 9 is an illustration of a graphene field-effect transistor.



FIG. 10 is a graph of I-Vg curves for various pH values.



FIG. 11 is a graph of frequency vs. normalized power spectral density for a silicon ISFET.



FIG. 12 is a graph of frequency vs. normalized power spectral density for a typical graphene FET.



FIG. 13 is a graph of frequency vs. normalized power spectral density for a graphene FET of the present invention.



FIG. 14 is a graph of noise vs. bias voltage.



FIG. 15 is a graph of Dirac voltage vs. current increase.



FIG. 16 is a graph of current increase vs. pH increase.



FIG. 17 is an illustration of molybdenum disulfide.



FIG. 18 is an illustration of black phosphorous.



FIG. 19 is an illustration of a nanotube.



FIG. 20 is an illustration of silicene.



FIG. 21 is an illustration of a semiconductor nanowire structure.





DETAILED DESCRIPTION OF THE INVENTION

As shown in FIGS. 1, 2, 3 and 4, an embodiment of the present invention is a chemically-sensitive field effect transistor that comprises an integrated circuit structure comprising a conductive source and a conductive drain and a channel. The channel extends from the conductive source to the conductive drain. An I-V curve or an I-Vg curve is shifted in response to a chemical reaction occurring on or near the chemically-sensitive field effect transistor.


As shown in FIG. 5, a system for analysis of biological or chemical materials is generally designated 10. The biological material is preferably a nucleic acid, other biological molecule, protein, or the like. The analysis is performed for whole genome analysis, genome typing analysis, genomic panels, exome analysis, micro-biome analysis, and clinical analysis. The clinical analysis comprises cancer analysis, NIPT analysis or UCS analysis. The system 10 preferably includes a fluidics component 20, an array 30 of sensors, a circuitry component 40 and a computing component 50. The system 10 also preferably includes at least a reference electrode. The fluidics component 20 is used to deliver reagents to the array of sensors and may comprise reagent supplies connected by tubing to the array of sensors 30. The fluidics component 20 comprises valves, manifolds or other flow control structures to tightly administer the composition, amount, timing and duration of fluid flow in the system.


As shown in FIGS. 1-4, the chemically-sensitive field-effect transistor 32 preferably includes a conductive source, a conductive drain, and a channel extending from the conductive source to the conductive drain. The conductive source and conductive drain are provided by a conductive element 34, such as a wiring trace or electrode. Depending on the fabrication process common semiconductor wiring trace materials are copper or aluminum—although others are known in the art such as gold or platinum. It is advantageous to match the work function of the conductive element 34 with the material comprising the channel 33. The preferred embodiment has conductive elements 34 with a work function compatible with graphene (e.g. Pt is a good choice) and with a contact structure that provides the lowest contact resistance possible. Although FIG. 1 shows the conductive elements 34 (source and drain) contacting the channel from the bottom, it is also possible for the conductive elements to contact the channel from the top. It is further possible that in some designs it would be preferable for one conductive element 34 (source or drain) to contact the channel from one direction while the complementary conductive element (drain or source, respectively) contacts the channel from the opposing direction. The actual contact from the conductive element 34 to the channel 33 may be with the conductive element 34 contacting a surface of the channel 33. Alternatively the conductive element 34 may be structured as a via that extends through the material of the channel 33—thus contacting the channel on a perimeter of the hole through the channel 33. Furthermore intermediate materials may be used to enhance the contact from the conductive material 34 to the channel 33.


The channel 33 overlies a lower dielectric layer 37. SiO2 is a common dielectric used in semiconductor fabrication and can be used for this purpose. Alternatively other materials may be chosen that due to their structure allow the chemically-sensitive FET to operate at a high level (e.g. have enhanced mobility in the channel). In a preferred embodiment where the channel 33 is comprised of graphene the lower dielectric layer 37 is comprised of hexagonal boron nitride (hBN). Since both hBN and graphene have a hexagonal crystal lattice structure with very similar lattice spacing—the hBN does not distort the graphene lattice—thus allowing for higher carrier mobility in the graphene.


The channel 33 is preferably composed of a one-dimensional transistor material or a two-dimensional transistor material. In a preferred embodiment the two-dimensional material is graphene, as shown FIG. 7. In another preferred embodiment the one-dimensional material is one or more Carbon NanoTubes (CNTs), as shown in FIG. 19. To achieve the best transistor transconductance (which relates to the sensitivity of the sensors in the sensor array 30) it is preferred to have the shorted channel length possible. A preferred length of the channel 33 from the source to the drain ranges is less than 1 micron, and more preferably is less than 500 nm, and more preferably is less than 50 nm, and more preferably still is as short as the fabrication process will allow without generating defects or results that render the device unusable. The most preferable channel length will be 20 nm or less. An alternative length is 0.05 micron to 3 microns. Conversely, the preferred width of the channel is as wide as possible. The width of the channel 33 in this case is not governed by the fabrication process as much as by the design requirements of the overall sensor chip. It is likely that many millions of sensors will be desired on the sensor chip. With this large number of sensors the individual sensor size and pitch (which directly affects the channel width) must be kept reasonably small otherwise the chip will so large as to be unable to be fabricated (e.g. exceeds the photolithography reticle size) or too expensive (due to the effect of defect density on a large chip size). A practical range of channel width is from 0.1 micron to 2 microns. An alternative width is 0.05 micron to 2 microns. In some cases it is desirable to increase the channel length to channel width ratio through the use of design techniques—for example, an interdigitated tooth and comb design can provide for short channel lengths and large channel widths within a relatively compact area. The channel 33 is preferably composed of a two-dimensional transistor material such as graphene, molybdenum disulfide (as shown in FIG. 17), other metal dichalcogenides, and black phosphorous (as shown in FIG. 18). Alternatively, the channel 33 is composed of a one-dimensional transistor material such as a carbon nanotube or a semiconductor nanowire (as shown in FIG. 21). Alternatively, the channel is composed of a silicene, as shown in FIG. 20. Additional alternative materials for the channel include borophene, WS2, boron nitride, stanene (2D tin), germanane, nickel HITP, and Mxenes (Ti2C, (Ti0.5, Nb0.5), V2C, Nb2C, Ti3C2, Ti3CN, Nb4C3 and Ta4C3). The most preferred material is graphene (FIG. 7).


Graphene is a two-dimensional mono layer of carbon atoms that form a lattice structure. The molecular structure of graphene, however, is very unique in that each carbon atom shares one of its four free valence electrons with three of its adjacent and planar carbon atoms such that each of the three planar carbon atoms is orientated at about a 120° with respect to the other three carbon atoms. This orientation gives graphene a honeycomb, lattice structure. Additionally, the fourth valence electron forms a pi bond, perpendicular to the three planar sigma-bonded carbon atoms, which is responsible for the unique electronic characteristics of graphene.


A single-layer graphene is a two-dimensional material. Its lattice structure forms regular hexagons with a carbon atom at each vertex. The bond length between adjacent carbon atoms is about 1.42 Å and the lattice constant is about 2.46 Å. This structure gives graphene two important characteristics: it makes graphene a semimetal (no bandgap) and it promotes rapid charge transport (mobility and high-field transport) at room temperature. Hence, in various instances, a graphene FET (G-FET or GFET used interchangeably), as herein described may perform better as a biological sensor then a typical CMOS-FET device. For instance, with respect to hybridization detection and/or sequencing, a traditional MOSFET transistor may have fundamental limitations in its sensitivity (due to channel thickness and intervening insulating layers), whereas a GFET has a single atom thickness channel that can be in direct contact or very close proximity with a chemical reaction zone. Furthermore graphene (or other 1D or 2D transistors) has a much higher carrier mobility than the doped silicon used in a MOSFET or IS_FET. This gives the herein disclosed GFETs increased sensitivity to and faster detection of chemical reactions.


As shown in FIGS. 1A, 2A and 3A, a preferred embodiment of the chemically-sensitive field-effect transistor 32 preferably includes a dielectric layer (or oxide layer) 35 that covers the channel material. This dielectric layer 35 may be chosen because it is sensitive to a particular analyte of interest and so we can describe this as an analyte-sensitive dielectric layer 35. For example, during DNA sequencing, when a base nucleotide combines with its complementary base pair a hydrogen ion is released. The ability to detect the hydrogen ion release (or a plurality of such releases) by the chemically-sensitive FET sensor can be enhanced by having a layer that is particularly sensitive to the ion or analyte of interest—in this case hydrogen ions. Dielectric materials can be chosen for their hydrogen ion sensitivity in addition to their compatibility with fabrication processes. Some hydrogen ion sensitive dielectrics include tantalum oxide (Ta2O5), hafnium oxide (HfO2), aluminum oxide (Al2O3), titanium oxide (TiO2), hafnium silicate, zirconium silicate, zirconium dioxide, lanthanum oxide, titanium oxide, iron oxide, or yttrium oxide, and others. A preferred material for the analyte-sensitive dielectric layer 35 is tantalum oxide (Ta2O5). The analyte-sensitive dielectric layer 35 is preferably thinner than 150 nm, and more preferably thinner than 60 nm, and most preferably thinner than 30 nm. In an alternative embodiment, the analyte-sensitive dielectric layer 35 is comprised of two or more analyte-sensitive dielectric layer layers. If an etching process is used to define the well structures 38, it can be desirable for the analyte-sensitive dielectric layer 35 to have a high etch selectivity in comparison to the material of the well layer 38—in this case acting as an etch stop for the well etch. It may be difficult to deposit a dielectric material onto clean graphene since there are in the ideal case no bonds available on the graphene surface to bond to. The deposition process must have a component whereby initial adhesion of the deposited analyte-sensitive dielectric layer 35 is insured. This may be done by some appropriate physical or chemical pre-treatment of the graphene surface or by the addition of a pre-cursor layer (e.g. a deposit or spun-on polymer) prior to the deposition of the analyte-sensitive dielectric layer. A preferred method for depositing the dielectric layer 35 comprises Atomic Layer Deposition (ALD). In some embodiments an analyte-sensitive dielectric layer 35 will neither be required nor used.


Preferably, a well structure 38 is positioned on or over a portion of an exterior surface of the analyte-sensitive dielectric layer 35 which in turn is on or over the channel 33 of a sensor 31, and the well structure defines an opening allowing for direct contact with the analyte-sensitive dielectric layer 35. The well structure 38 is preferably composed of an insulator material. The insulator material for the well structure is preferably an inorganic material, such as silicon oxide or silicon nitride. Alternatively, the insulator material for the well structure is an organic material such as a polyimide, a benzocyclobutene (“BCB”) material, or other like materials. If an organic material is used it is preferably a photosensitive material so that it can be photo-imaged and developed directly without the need for a photoresist material. The size (diameter or equivalent width), shape and depth of the well must be matched to the size range of microbeads carrying DNA template strands. It is preferred that the well geometry only allows the possibility for one bead to be entrapped in the well.


As shown in FIG. 1A, a microbead is positioned within the well structure in proximity to the analyte-sensitive layer 35 and thereby near to the channel 38. For DNA sequencing the microbead has a plurality of DNA template strands that cover its surface and if the bead is porous or a gel material the DNA template strands may be throughout the bead material.


As shown in FIG. 6, an array 30 comprises a plurality of sensors. It is further possible that the reference electrode for supplying the solution gate voltage can be incorporated as part of the sensor chip or within the package holding the sensor chip. Reference electrodes are preferably comprised of platinum or Ag/AgCl.



FIG. 1A shows a solution-gate electrode 39 to supply the solution gate voltage to the fluid or solution. This is an electrode that is in electrical communication with the fluid at some point in the fluidics system 20 or within the chip package or over the chip. This solution gate 39 is sometimes referred to as a top or front gate. FIG. 1A additionally shows the option of providing a back gate 36 (sometimes referred to as a bottom gate). In this case the back gate voltage can be applied through a highly-doped and relatively conductive semiconductor substrate. An array of back gate 36 structures could also be constructed from an array of Through-Silicon-Vias (TSVs) that could bring the back gate voltage to the underside of the dielectric layer under the channel through a metal or other conductive via. While the following sections will concentrate on a description of the sensor 31 with only a solution gate 39, it can be advantageous to operate the sensor with a back gate 36 only or with a combination of a solution gate 39 and back gate 36. By combining a solution gate 39 with a back gate 36 is may be possible to increase the sensitivity of the sensor to the analyte of interest.


As shown in FIG. 8, an average sensitivity of a graphene FET (“GFET”) calculated as a function of liquid or solution gate potential. The GFET of the present invention approaches the theoretical 59 mV/pH maximum for an ISFET type device (referred to as the Nernst limit).



FIG. 10 illustrates the transfer characteristics of a 20×40 micron graphene-on-SiO2 SGFET (“solution gated FET”) at a constant drain-source voltage of Vds=50 mV for different pH values.


Accordingly, when using the device for sequencing a nucleic acid sample, the target nucleic acid sample may be coupled to or in proximity with the graphene coated surface of the reaction zone. This template sequence may then be sequenced and/or analyzed by performing one or more of the following steps. For example, a primer, and/or a polymerase, e.g., an RNA and/or DNA polymerase, and/or one or more substrates, e.g. deoxynucleotide triphosphates dATP, dGTP, dCTP, and dTTP, may be added, e.g., sequentially, to the reaction chamber, such as after the hybridization reaction begins so as to induce an elongation reaction. Once the appropriate substrate hybridizes to its complement in the template sequence, there will be a concomitant change in the individual electrical characteristic voltage, e.g., the source-drain voltage (Vsd), measured as a result of the new local gating effect.


Hence, for every elongation reaction with the appropriate, e.g., complementary, substrate there will be a change in the characteristic voltage. For instance, as described herein, a field-effect device for nucleic acid sequencing and/or gene detection is disposed in a sample chamber of a flow cell, and a sample solution, e.g., containing a polymerase and one or more substrates, may be introduced to the sample solution chamber. In various embodiments, a reference electrode may be disposed upstream, downstream or in fluid contact with the field-effect device and/or the source and/or drain may themselves serve as electrodes, such as for hybridization detection, and gate voltage may be applied whenever needed.


Particularly, in an exemplary elongation reaction, polynucleotides are synthesized if the added substrate is complementary to the base sequence of the target DNA primer and/or template. If the added substrate is not complementary to the next available base sequence, hybridization does not occur and there is no elongation. Since nucleic acids, such as DNAs and RNAs, have a negative charge in aqueous solutions, hybridization resulting in elongation can be incrementally determined by the change in the charge density in the reaction chamber or well 38. And because the substrates are added sequentially, it can readily be determined which nucleotide bound to the template thereby facilitating the elongation reaction. Accordingly, as a result of elongation, the negative charge on the graphene gate surface, insulating film surface, and/or the sidewall surface of the reaction chamber will be increased. This increase may then be detected, such as a change in the gate-source voltage, as described in detail herein. By determining the addition of which substrate resulted in a signal of change in gate-source voltage, the base sequence identity of the target nucleic acid can be determined and/or analyzed.


More specifically, the field-effect transistor, such as for nucleic acid elongation and/or hybridization detection, may be associated with a buffered solution that is added to the reaction chamber, which can then be used to determine if an elongation reaction has taken place. Particularly, once the template is associated with the substrate, the reaction mixture containing a polymerase, e.g., a Taq polymerase, and a first nucleic acid substrate, e.g., a dATP, is added to the buffer solution to carry out the elongation reaction on or over the analyte-sensitive dielectric layer 35 or the graphene channel 33 coated insulating film of the reaction chamber surface. If the dATP is a complement to the next available reaction site in the isolated template a binding event, e.g., a hybridization reaction, will occur and the antisense strand of the growing sequence will be elongated, and detected by the GFET transistor.


For example, if adenine (A) is complementary to the base thymine (T) on the target template adjacent to the 3′-terminus of the nucleic acid template, an elongation reaction occurs, resulting in synthesis of one adenine. In such instance, the enzyme, Taq DNA polymerase, and the substrate may be washed away from the channel portion 33 and reaction chamber 38, and a buffer solution, e.g., a phosphoric acid buffer solution, e.g., having a pH of about 6, may be introduced on or over the graphene channel surface 33 or the analyte-sensitive dielectric layer 39 to measure changes in the source-drain voltage. If hybridization has occurred there will be a change in the source-drain voltage and it will be detected. However, if the dATP is not a match, there will be no hybridization, and if no hybridization, there will be no elongation. Consequently, a second reaction mixture containing another, different nucleotide substrate, e.g., dCTP and the enzyme polymerase, and the like will be added to the reaction chamber or well 38 under conditions suitable for hybridization, which if it occurs will be detected by the GFET. If not, then the steps will be repeated with the next substrate. These steps may be repeated until the nucleic acid sample has been completely sequenced. In various instances, the temperature within the reaction chamber may be controlled, for instance, it may be set to 74° C., such as by using a temperature sensor and/or a heater integrated in the field-effect device.


Consequently, if a hybridization reaction takes place there will be a resultant change to the threshold voltage, which will be increased, e.g., by 4 mV, from before the elongation reaction. The shift of the threshold voltage in the positive direction indicates that a negative charge was generated on or over the graphene channel surface 33. It can be understood from this that synthesis of one base caused by the elongation reaction was detectable as a change in threshold voltage. A second elongation reaction may then take place and be repeated until the entire target nucleic acid has been sequenced.


More particularly, in such a configuration as represented in the figures, the drain current of the transistor may be modulated by the electrical charge carried by the nucleotide molecules involved in the hybridization and/or sequencing reactions. For example, after a binding event, the charge in the reaction zone increases resulting in a change in the output current that may be measured. Such a measurement may be made in accordance with the following equation:







V
THF

=


V

TH





0


-



Q
com

+

Q
0




C
C

+

C
F








Such as where CC represents the current at the control capacitor, and CF represents the current at the parasitic capacitor. VTHF represents the effective threshold voltage of the transistor (Dirac point), and VTH0 represents the native threshold voltage (original Dirac point). Q0 represents the electric charge initially trapped in the floating gate, and QDNA represents the total charge of hybridization complex.


For instance, a nucleic acid from a sample to be sequenced or representative of a probe to be targeted may be immobilized on the bottom surface or the sidewall of the sample solution well chamber 38. A Taq DNA polymerase and a nucleotide substrate may then be introduced to the sample solution chamber to induce an elongation reaction. As a result, DNAs may be synthesized along the surface in the vertical or lateral direction, e.g., in parallel to the surface of the graphene coated channel surfaces. In such an instance, as the source-drain current vs gate voltage characteristic changes by the electrostatic interaction with the charged particles (electrons) in the well, and the synthesis of the DNA is in the direction that is transverse or parallel to the graphene channel surface, this keeps the distance between the DNA and the electrons constant, thereby helping to maintain a constant electrostatic interaction. Thus, the base sequence of a template nucleic acid having a large base length can be sequenced and/or analyzed. In other embodiments, a nucleic acid probe may be immobilized on the surface of the reaction zone, as described above, and used in a hybridization reaction so as to detect genetic variation and/or the presence of a genetic disease.


In various instances, in order to conduct parallel analysis of a plurality of nucleic acid templates, the number of the transistors may be equal to or higher than the number and/or types of DNAs to be sequenced and/or analyzed. In certain instances, each nucleic acid template or probe may be an oligonucleotide or a fragment of DNA or RNA that may be constituted from about 100 to about 1000 bases, such as from 200 to about 800 bases, for instance, from about 300 or about 500 bases to about 600 or 700 bases or more or somewhere in between. However, in various instances, a fragment of nucleic acid having 100 bases or fewer may also be used.


Additionally, as indicated above, the device 10 may also be used in various different DNA/RNA hybridization reactions, such as for the purpose of determining a genetic variation and/or for detecting the presence of a genetic marker for a disease. In such an instance, a nucleic acid probe may be coupled to a bottom or side graphene coated or analyte-sensitive dielectric layer coated surface of the reaction chamber or well 38, per above. As indicated, the probe may be of any suitable length but in various instances from about 5 or 10 to about 1000 bases, such as from 20 or about 50 to about 700 or about 800 bases, for instance, from about 100 or about 200 bases to about 300 bases including about 400 or about 500 bases to about 600 or 700 bases or more or somewhere in between.


For instance, in one exemplary instance, a nucleic acid probe containing about 10 to 15 bases coding for a gene sequence of interest that has been previously amplified, such as by polymerase chain reaction (PCR), may be immobilized on the channel, analyte-sensitive dielectric layer or side surface of the reaction chamber 38 of the field-effect transistor. For example, once isolated and amplified, the base of the template may be modified so as to be attached to the graphene or analyte-sensitive dielectric coated surface, and/or may be coupled to a secondary substrate, such as a glass or plastic bead that has been chemically treated so as to be coupled therewith. Once immobilized, the reaction chamber containing the probes, either on a secondary substrate or directly coupled with a chamber surface, may be reacted with a sample solution containing a number genes including a target gene of interest to be measured such that when a nucleic acid probe having a complementary base sequence to the target gene is immobilized on the gate, gate insulating film or the sidewall surface of the sample solution well structure, or on a secondary substrate immobilized within the reaction chamber of the field-effect device for gene detection, the target gene hybridizes with the nucleic acid probe under appropriate reaction conditions and the target gene and the nucleic acid probe form a double strand, the result of which hybridization reaction may be detected.


A GFET array sets forth a two dimensional GFET sensor array chip that in this instance is based on a column and row design, although other designs are also possible. The system further includes a row and column decoder, as well as circuitry for performing the requisite sensing, detecting, and processing so as to measure the sensory data. Hence, also included is sensing, measurement, and other associated readout data.


Accordingly, in various instances, a one or two-dimensional GFET array, as described herein, may be fabricated on a microchip in accordance with the methods herein disclosed. In various instances, the array chip may include a number of GFET sensors that may be arranged in columns and/or rows. A typical number of sensors may include GFET sensor elements, described herein as “sensors,” that may be arranged in a 16 sensor by 16 sensor column/row array configuration. As depicted, the array includes two columns, but typically may include sixteen columns, arranged side by side, where each column includes 16 rows. Particularly, each column of the array includes up to 16 sensors. Each column may be configured so as to include a current source ISOURCE that may be shared by all sensors of the column. However, in various other embodiments, each sensor may have its own current source, or the array itself may have a single current source. Additionally, each GFET sensor may include a GFET, as described above, having an electrically coupled source and/or drain and/or body, and may further include one or more switches, such as a plurality of switches S1 and S2 that may be configured so as to be responsive to one of the up to sixteen row select signals (RSEL, and it's complements). More particularly, a row select signal and its complement may be generated simultaneously to “enable” or select a given sensor of the selected column, and such signal pairs may be generated in some sequence to successively enable different sensors of the column, e.g., together or one at a time, such as sequentially. Other architectures may be employed to address the sensors—including architectures that may only require one access transistor per sensor.


A row decoder may also be provided as part of the system. In such an instance, the row decoder may be configured so as to provide up to sixteen pairs of complementary row select signals, wherein each pair of row select signals may be adapted so as to simultaneously or sequentially enable one sensor in each column so as to provide a set of column output signals from the array, e.g., based on the respective source voltages VSa through VSb, etc. of the enabled row of GFETs. The row decoder may be implemented as a conventional four-to-sixteen decoder (e.g., a four-bit binary input ROW1-ROW4 to select one of 24 outputs). The set of column output signals VSa through VSb for an enabled row of the array is applied to switching logic, which may be configured to include up to sixteen transmission gates Sa through Sb (e.g., one transmission gate for each output signal).


As above, each transmission gate of the switching logic may be implemented using an n-channel or p-channel MOSFET, in a bottom or top gate configuration, or both to ensure a sufficient dynamic range for each of the output signals VSa through VSb. The column decoder, like the row decoder, may be implemented as a conventional four-to-sixteen decoder and may be controlled via the four-bit binary input COL1-COL4 to enable one of the transmission gates Sa through Sb of the switching logic at any given time, so as to provide a single output signal VS from the switching logic. This output signal VS may be applied to a 10-bit analog to digital converter (ADC) to provide a digital representation D1-D10 of the output signal VS corresponding to a given sensor of the array.


As noted earlier, individual GFETs and arrays of GFETs such as those discussed above may be employed as sensing devices in a variety of applications involving chemistry and biology. In particular, such GFETs may be employed as pH sensors in various processes involving nucleic acids such as DNA. In general, the development of rapid and sensitive nucleic acid hybridization and sequencing methods, as herein described, e.g., utilizing automated DNA sequencers, may significantly advance the understanding of biology.


It should be noted, that with respect to the various arrays disclosed herein according to various embodiments of the present disclosure may be fabricated according to conventional CMOS fabrication techniques, as described above, as well as modified CMOS fabrication techniques (e.g., to facilitate realization of various functional aspects of the GFET arrays discussed herein, such as additional deposition of graphene and/or other materials, process steps to mitigate trapped charge, etc.) and other semiconductor fabrication techniques beyond those conventionally employed in typical CMOS fabrication (e.g BiCMOS). Additionally, various lithography techniques may be employed as part of an array fabrication process. For example, in one exemplary implementation, a lithography technique may be employed in which appropriately designed blocks are “stitched” together by overlapping the edges of a step and repeat lithography exposures on a wafer substrate by approximately 0.2 micrometers. In a single exposure, the maximum die size typically is approximately 21 millimeters by 21 millimeters. By selectively exposing different blocks (sides, top & bottoms, core, etc.) very large chips can be defined on a wafer (up to a maximum, in the extreme, of one chip per wafer, commonly referred to as “wafer scale integration”).


In one embodiment, the array includes 512 columns with corresponding column bias/readout circuitry (one for each column), wherein each column includes geometrically square sensors, each having a size of approximately 9 micrometers by 9 micrometers (e.g., the array may be up to 512 columns by 512 rows). In various instances, the entire array (including sensors together with associated row and column select circuitry and column bias/readout circuitry) may be fabricated on a semiconductor die as an application specific integrated circuit (ASIC), structured ASIC, or as a field programmable gate array, such as having dimensions of approximately 7 millimeters by 7 millimeters.


Various power supply and bias voltages useful for array operation are provided to the array via electrical connections (e.g., pins, metal pads) and labeled for simplicity in block as “supply and bias connections.” The array may also include a row select shift register, one or more, e.g., two sets of column select shift registers, and one or more, e.g., two, output drivers, which output drivers are configured to provide two parallel output signals from the array, Vouta and Voutb, representing sensor measurements. The various power supply and bias voltages, control signals for the row and column shift registers, and control signals for the column bias/readout circuitry may be provided by an array controller, which controller may also read the output signals Vouta and Voutb (and other optional status/diagnostic signals) from the array.


Configuring the array such that multiple regions (e.g., multiple columns) of the array may be read at the same time via multiple parallel array outputs (e.g., Vouta and Voutb) facilitates increased data acquisition rates.


It should be noted that, in various embodiments of the array, one or more of the columns, e.g., the first and last columns, as well as the first and/or last sensors of each of the columns may be configured as “reference” or “dummy” sensors. For instance, the dummy sensors of an array, e.g., the topmost metal layer of each dummy sensor may be tied to the same metal layer of other dummy sensors and may be made accessible as a terminal of the chip, which in turn may be coupled to a reference voltage VREF. Such reference voltage VREF may be applied to the bias/readout circuitry of respective columns of the array. In some exemplary implementations, preliminary test/evaluation data may be acquired from the array based on applying the reference voltage VREF and selecting and reading out dummy sensors, and/or reading out columns based on the direct application of VREF to respective column buffers (e.g., via the CAL signal), to facilitate offset determination (e.g., sensor-to-sensor and column-to-column variances) and array calibration. The calibration data can be stored for each sensor location either just prior to a sequencing session, or preferentially at the end of the device manufacturing process. The calibration data can be stored on-chip in non-volatile memory.


A more detailed description of a system for analysis of biological and chemical materials is set forth in van Rooyen et al., U.S. Patent Publication Number 20140371110 for Bioinformatics Systems, Apparatuses, and Methods Executed On An Integrated Circuit Processing Platform, which is hereby incorporated by reference in its entirety. A more detailed description of a system for analysis of biological and chemical materials is set forth in van Rooyen et al., U.S. Patent Publication Number 20140309944 for Bioinformatics Systems, Apparatuses, and Methods Executed On An Integrated Circuit Processing Platform, which is hereby incorporated by reference in its entirety. A more detailed description of a system for analysis of biological and chemical materials is set forth in van Rooyen et al., U.S. Patent Publication Number 20140236490 for Bioinformatics Systems, Apparatuses, and Methods Executed On An Integrated Circuit Processing Platform, which is hereby incorporated by reference in its entirety. A more detailed description of a system for analysis of biological and chemical materials is set forth in van Rooyen et al., U.S. Pat. No. 9,014,989 for Bioinformatics Systems, Apparatuses, and Methods Executed On An Integrated Circuit Processing Platform, which is hereby incorporated by reference in its entirety. A more detailed description of a system for analysis of biological and chemical materials is set forth in U.S. Provisional Application No. 61/826,381, titled System and Method for Computation Geneomic Pipeline, filed May 22, 2013, which is hereby incorporated by reference in its entirety. A more detailed description of a system for analysis of biological and chemical materials is set forth in U.S. Patent Publication Number 20150339437, for Dynamic Genome Reference Generation For Improved NGS Accuracy And Reproducibility, filed Feb. 24, 2015, which is hereby incorporated by reference in its entirety. A description of a GFET is set forth in van Rooyen, U.S. Provisional Patent Application No. 62/094,016, filed on Dec. 18, 2014, for Graphene FET Devices, Systems, And Methods Of Using The Same For Sequencing Nucleic Acids, which is hereby incorporated by reference in its entirety. A description of a GFET is set forth in Hoffman et al., U.S. Provisional Patent Application No. 62/130,594, filed on Mar. 9, 2015, for Chemically Sensitive Field Effect Transistor, which is hereby incorporated by reference in its entirety. A more detailed description of a GFET is set forth in Hoffman et al., U.S. Provisional Patent Application No. 62/206,228, filed on Aug. 17, 2015, for Chemically Sensitive Field Effect Transistor, which is hereby incorporated by reference in its entirety. A more detailed description of a GFET is set forth in Hoffman et al., U.S. Provisional Patent Application No. 62/199,987, filed on Aug. 1, 2015, for Chemically Sensitive Field Effect Transistor, which is hereby incorporated by reference in its entirety.


From the foregoing it is believed that those skilled in the pertinent art will recognize the meritorious advancement of this invention and will readily understand that while the present invention has been described in association with a preferred embodiment thereof, and other embodiments illustrated in the accompanying drawings, numerous changes modification and substitutions of equivalents may be made therein without departing from the spirit and scope of this invention which is intended to be unlimited by the foregoing except as may appear in the following appended claim. Therefore, the embodiments of the invention in which an exclusive property or privilege is claimed are defined in the following appended claims.


REFERENCE NUMERALS




  • 10 System


  • 20 Fluidics component


  • 21 Fluid


  • 22 Bead


  • 23 DNA strand


  • 30 Array


  • 31 Sensor


  • 32 Chemically-sensitive field-effect transistor


  • 33 Channel


  • 34 Conductive element


  • 35 Analyte-sensitive dielectric layer


  • 36 Back gate


  • 37 Lower dielectric layer


  • 38 Well structure


  • 39 Solution or Top gate


  • 40 Circuitry component


  • 50 Computing component


Claims
  • 1. A chemically-sensitive field effect transistor having a multi-layered structure for performing a sequencing reaction involving the sequencing of strands of nucleic acids, the field effect transistor, comprising: a substrate layer having an extended body;a first insulating layer positioned above the extended body of the substrate layer;a second insulating layer positioned above the first insulating layer;a source electrode and a drain electrode each having a top surface and a bottom surface, the top surface separated from the bottom surface by opposing outer and inner side portions, each of the opposed side portions and each of the bottom surfaces of the source and drain electrodes being disposed within the first insulating layer, the source electrode being separated from the drain electrode by a distance;a graphene layer positioned between the first insulating layer and second insulating layer and extending between the outer side portion of the source electrode and the outer side portion of the drain electrode thereby forming a channel between the source electrode and drain electrode, the graphene layer contacting the top surface of the source electrode and drain electrode; anda reaction chamber formed by a well structure provided in the second insulating layer, the well structure having an opening at a top surface of the second insulating layer and extending toward the graphene layer the graphene layer forming a bottom layer of the reaction chamber, the reaction chamber configured for receiving and retaining one or more reactants therein for performing the sequencing reaction.
  • 2. The chemically-sensitive field effect transistor according to claim 1, wherein the multi-layered structure is configured so as to shift or change a characteristic of an I-V curve or an I-Vg curve in response to a chemical reaction occurring within the reaction chamber of the well of the chemically-sensitive field effect transistor.
  • 3. The chemically-sensitive field effect transistor according to claim 2, further comprising an analyte-sensitive dielectric layer.
  • 4. The chemically-sensitive field effect transistor according to claim 3, wherein the analyte-sensitive dielectric layer comprises an oxide layer.
  • 5. The chemically-sensitive field effect transistor according to claim 3, wherein the second insulating layer is composed of a polymer, polyimide, BCB, inorganic material, silicon oxide, a silicon nitride, a silicon oxynitride or a silicon carbide.
  • 6. The chemically-sensitive field effect transistor according to claim 1, wherein the conductive source and the conductive drain are each comprised of a copper material, an aluminum material, a platinum material, or a gold material.
  • 7. The chemically-sensitive field effect transistor according to claim 6, wherein the channel has a thickness of 50 nanometers or less.
  • 8. A chemically-sensitive field effect transistor having a multi-layered structure for performing a biological reaction involving one or more of a deoxyribonucleic acid, a ribonucleic nucleic acid, and a protein, the field effect transistor comprising: a substrate layer having an extended body;a first insulating layer positioned above the extended body of the substrate layer;a source electrode and a drain electrode positioned in or over the first insulating layer, the source electrode separated from the drain electrode by a distance;a second insulating layer positioned above the first insulating layer and proximate the source and drain electrodes;a graphene layer positioned between the first and second insulating layers and extending between the source and drain electrodes thereby forming a channel between the source electrode and drain electrode; anda reaction chamber formed by a well structure provided in the second insulating layer, the well structure having an opening at a top surface of the second insulating layer and extending toward the graphene layer, the graphene layer substantially extending between an outer side portion of the drain electrode and an outer side portion of the source electrode and forming a bottom layer within the reaction chamber, the reaction chamber configured for receiving and retaining one or more of a deoxyribonucleic acid, a ribonucleic nucleic acid, and a protein therein for performing the biological reaction.
  • 9. The chemically-sensitive field effect transistor according to claim 8, wherein the multi-layered structure is configured so as to shift an I-V curve or an I-Vg curve in response to the biological reaction occurring within the chamber of the well of the chemically-sensitive field effect transistor.
  • 10. The chemically-sensitive field effect transistor according to claim 9, wherein a length of the channel from the source to the drain ranges from 0.05 micron to 2 microns, and a width of the channel ranges from 0.05 micron to 5 microns.
  • 11. The chemically-sensitive field effect transistor according to claim 10, further comprising an analyte-sensitive dielectric layer.
  • 12. The chemically-sensitive field effect transistor according to claim 8, wherein the biological reaction comprises a member selected from the group consisting of a nucleic acid sequencing reaction, a nucleic acid hybridization reaction, and a protein detection reaction, and the chemically-sensitive field effect transistor is configured for detecting a result of the reaction.
  • 13. A chemically-sensitive field effect transistor having a multi-layered structure for performing a biological reaction involving fluidic reagents within a fluid, the field effect transistor comprising: a substrate layer having an extended body;a first insulating layer positioned above the extended body of the substrate layer;a source electrode and a drain electrode positioned in or over the first insulating layer, the source electrode and the drain electrode being separated by a distance;a second insulating layer positioned above the first insulating layer and proximate the source and drain electrodes;a graphene layer positioned between the first and second insulating layers and substantially extending between an outer side portion of the drain electrode and an outer side portion of the source electrode to form a channel between the source and drain electrodes; anda reaction chamber formed by a well structure provided in the second insulating layer, the well structure having an opening therein, the opening defined by opposed side portions and a bottom formed at least by the graphene layer, the reaction chamber configured for receiving and retaining one or more of the reagents in a fluid therein for performing a biological reaction.
  • 14. The chemically-sensitive field effect transistor according to claim 13, wherein the one-dimensional transistor material or two-dimensional transistor material selected from the group consisting of a single layer planar graphene, black phosphorous, silicene, borophene, tungsten disulfide, germanane, nickel HITP, stanene and Mxenes.
  • 15. The chemically-sensitive field effect transistor according to claim 13, further comprising an analyte-sensitive dielectric layer.
  • 16. The chemically-sensitive field effect transistor according to claim 15, wherein the analyte-sensitive dielectric layer comprises an oxide layer.
  • 17. The chemically-sensitive field effect transistor according to claim 13, wherein the biological reaction involves a biological material selected from the group consisting of a nucleotide, nucleic acid, and a protein, and the chemically-sensitive field effect transistor is configured for detecting the biological material.
  • 18. A chemically-sensitive field effect transistor having a multi-layered structure for performing a biological reaction, the field effect transistor comprising: a substrate layer, the substrate layer having an extended body;a first insulating layer positioned above the extended body of the substrate layer;a source electrode and a drain electrode positioned in the first insulating layer, the source electrode separated from the drain electrode by a distance;a second insulating layer positioned above the first insulating layer and proximate the source and drain electrodes;a graphene layer positioned between the first and second insulating layers and substantially extending between an outer side portion of the source electrode and an outer side portion of the drain electrodes to form a channel there-between; anda reaction chamber formed by a well structure provided in the second insulating layer, the well structure having an opening, the opening including opposing side portions and a bottom formed by at least the graphene layer, the reaction chamber configured for receiving and retaining one or more reactants therein for performing the biological reaction.
  • 19. The chemically-sensitive field effect transistor according to claim 18, wherein the multi-layered structure is configured so as to shift or change a characteristic of an I-V curve or an I-Vg curve in response to the biological reaction occurring within the reaction chamber of the well of the chemically-sensitive field effect transistor.
  • 20. The chemically-sensitive field effect transistor according to claim 19, further comprising an analyte-sensitive dielectric layer.
  • 21. The chemically-sensitive field effect transistor according to claim 20, wherein the analyte-sensitive dielectric layer comprises an oxide layer.
  • 22. The chemically-sensitive field effect transistor according to claim 19, wherein the biological reaction involves a biological material selected from the group consisting of a nucleotide, nucleic acid, and a protein, and the chemically-sensitive field effect transistor is configured for detecting the biological material.
CROSS REFERENCES TO RELATED APPLICATIONS

The present application claims priority to U.S. Provisional Patent Application No. 62/206,228, filed on Aug. 17, 2015, U.S. Provisional Patent Application No. 62/199,987, filed on Aug. 1, 2015, U.S. Provisional Patent Application No. 62/130,594, filed on Mar. 9, 2015, and U.S. Provisional Patent Application No. 62/094,016, filed on Dec. 18, 2014, all of which are hereby incorporated by reference in their entireties.

US Referenced Citations (513)
Number Name Date Kind
3377893 Shorb Apr 1968 A
3466874 Holl Sep 1969 A
3564151 Shlesinger, Jr. Feb 1971 A
3605428 Smith et al. Sep 1971 A
3691109 Larsen Sep 1972 A
3772069 Daniel Nov 1973 A
3828094 Widdig et al. Aug 1974 A
3892139 Harris Jul 1975 A
3931401 Prasad et al. Jan 1976 A
5397863 Afzali-Ardakani et al. Mar 1995 A
5556899 Afzali-Ardakani et al. Sep 1996 A
5571852 Afzali-Ardakani et al. Nov 1996 A
5591285 Afzali-Ardakani et al. Jan 1997 A
5639660 Kinet et al. Jun 1997 A
5701256 Marr et al. Dec 1997 A
5958784 Benner Sep 1999 A
6001611 Will Dec 1999 A
6377893 Benner Apr 2002 B1
6466874 Eisenberg et al. Oct 2002 B1
6564151 Pellegrini et al. May 2003 B1
6605428 Kilger et al. Aug 2003 B2
6691109 Bjornson et al. Feb 2004 B2
6772069 Eisenberg et al. Aug 2004 B1
6828094 Kilger et al. Dec 2004 B2
6892139 Eisenberg et al. May 2005 B2
6931401 Gibson et al. Aug 2005 B2
7008764 Honold et al. Mar 2006 B1
7247877 Hakey et al. Jul 2007 B2
7253431 Afzali-Ardakani et al. Aug 2007 B2
7333980 Bjornson et al. Feb 2008 B2
7462468 Williams et al. Dec 2008 B1
7484423 Hakey et al. Feb 2009 B2
7492015 Chen et al. Feb 2009 B2
7504132 Afzali-Ardakani et al. Mar 2009 B2
7514063 Tulevski et al. Apr 2009 B1
7544546 Afzali-Ardakani et al. Jun 2009 B2
7612270 Zhu Nov 2009 B1
7670810 Gunderson et al. Mar 2010 B2
7727505 Afazali-Ardakani et al. Jun 2010 B2
7732119 Afzali-Ardakani et al. Jun 2010 B2
7745118 Green et al. Jun 2010 B2
7750908 Kincaid et al. Jul 2010 B2
7761462 Bjornson et al. Jul 2010 B2
7771695 Afzali-Ardakani et al. Aug 2010 B2
7855133 Afzali-Ardakani et al. Dec 2010 B2
7867469 Afzali-Ardakani et al. Jan 2011 B2
7879307 Afzali-Ardakani et al. Feb 2011 B2
7883685 Afzali-Ardakani et al. Feb 2011 B1
7888528 Afzali-Ardakani et al. Feb 2011 B2
7917299 Buhler et al. Mar 2011 B2
7932029 Lok Apr 2011 B1
7948015 Rothberg et al. May 2011 B2
7951424 Afzali-Ardakani et al. May 2011 B2
7955585 Afzali-Ardakani et al. Jun 2011 B2
7955931 Appenzeller et al. Jun 2011 B2
7982274 Afzali-Ardakani et al. Jul 2011 B2
7993842 McKeman et al. Aug 2011 B2
8017934 Appenzeller et al. Sep 2011 B2
8032305 Shibuya Oct 2011 B2
8039334 Furukawa et al. Oct 2011 B2
8039909 Afzali-Ardakani et al. Oct 2011 B2
8057984 Afzali-Ardakani et al. Nov 2011 B2
8084012 Afzali-Ardakani et al. Dec 2011 B2
8095508 Chamberlain et al. Jan 2012 B2
8124463 Chen et al. Feb 2012 B2
8138102 Afzali-Ardakani et al. Mar 2012 B2
8138491 Appenzeller et al. Mar 2012 B2
8138492 Afzali-Ardakani et al. Mar 2012 B2
8143030 Maxham et al. Mar 2012 B2
8153375 Travers et al. Apr 2012 B2
8182989 Bignell et al. May 2012 B2
8182993 Tomaney et al. May 2012 B2
8209130 Kennedy et al. Jun 2012 B1
8211735 Graham et al. Jul 2012 B2
8211741 Appenzeller et al. Jul 2012 B2
8217433 Fife Jul 2012 B1
8227171 Afzali-Ardakani et al. Jul 2012 B2
8244479 Kain et al. Aug 2012 B2
8283453 Afzali-Ardakani et al. Oct 2012 B2
8283703 Solomon Oct 2012 B2
8293607 Afzali-Ardakani et al. Oct 2012 B2
8296075 Den Hartog Oct 2012 B2
8306757 Rothberg et al. Nov 2012 B2
8309330 Travers et al. Nov 2012 B2
8329400 Lok Dec 2012 B2
8383345 Shendure et al. Feb 2013 B2
8383369 Maxham et al. Feb 2013 B2
8394727 Afzali-Ardakani et al. Mar 2013 B1
8395774 Afzali et al. Mar 2013 B2
8445945 Rothberg et al. May 2013 B2
8455193 Travers et al. Jun 2013 B2
8455297 Avouris et al. Jun 2013 B1
8455311 Solomon Jun 2013 B2
8463555 Zhang Jun 2013 B2
8465647 Bol et al. Jun 2013 B2
8471249 Chiu et al. Jun 2013 B2
8481413 Afzali-Ardakani et al. Jul 2013 B2
8486630 Pan et al. Jul 2013 B2
8491769 Afzali-Ardakani et al. Jul 2013 B2
8492293 Afzali-Ardakani et al. Jul 2013 B1
8492748 Chang et al. Jul 2013 B2
8512458 Holmes et al. Aug 2013 B2
8515682 Buhler et al. Aug 2013 B2
8518829 Dang et al. Aug 2013 B2
8524487 Fife Sep 2013 B2
8535882 Christians et al. Sep 2013 B2
8546246 Lin et al. Oct 2013 B2
8554492 Ahn et al. Oct 2013 B2
8557097 Afzali-Ardakani et al. Oct 2013 B2
8558288 Rothberg et al. Oct 2013 B2
8574892 Su Nov 2013 B2
8587065 Chen et al. Nov 2013 B2
8594951 Homer Nov 2013 B2
8598569 Afzali-Ardakani et al. Dec 2013 B2
8603792 Nikiforov et al. Dec 2013 B2
8604559 Afzali-Ardakani et al. Dec 2013 B2
8609481 Franklin et al. Dec 2013 B1
8610989 Avouris et al. Dec 2013 B2
8614436 Solomon Dec 2013 B2
8617941 Farmer et al. Dec 2013 B2
8620881 Chamberlain et al. Dec 2013 B2
8628940 Sorenson et al. Jan 2014 B2
8637374 Appenzeller et al. Jan 2014 B2
8642432 Afzali-Ardakani et al. Feb 2014 B2
8674412 Franklin et al. Mar 2014 B2
8688388 Dzakula et al. Apr 2014 B2
8698226 Jain et al. Apr 2014 B2
8700341 Rava et al. Apr 2014 B2
8716029 Kim et al. May 2014 B1
8716597 Mann et al. May 2014 B2
8725422 Halpern et al. May 2014 B2
8738300 Porreca et al. May 2014 B2
8741678 Chen et al. Jun 2014 B2
8741751 Cao et al. Jun 2014 B2
8741756 Franklin et al. Jun 2014 B2
8751166 Friedlander et al. Jun 2014 B2
8751452 Chamberlain et al. Jun 2014 B2
8753816 Rigatti et al. Jun 2014 B2
8753912 Graham et al. Jun 2014 B2
8754393 Cao et al. Jun 2014 B2
8765547 Farmer et al. Jul 2014 B2
8766345 Farmer et al. Jul 2014 B2
8772141 Afzali-Ardakani et al. Jul 2014 B2
8772910 Afzali-Ardakani et al. Jul 2014 B2
8779414 Chang et al. Jul 2014 B2
8785262 Farmer et al. Jul 2014 B2
8785911 Chen et al. Jul 2014 B2
8786018 Farmer et al. Jul 2014 B2
8795961 Rank et al. Aug 2014 B2
8796642 Boday et al. Aug 2014 B2
8796668 Lin et al. Aug 2014 B2
8797059 Boday et al. Aug 2014 B2
8803129 Chang et al. Aug 2014 B2
8803131 Lin et al. Aug 2014 B2
8803132 Farmer et al. Aug 2014 B2
8805148 Avouris et al. Aug 2014 B2
8809153 Afzali-Ardakani et al. Aug 2014 B2
8809837 Farmer et al. Aug 2014 B2
8816328 Chang et al. Aug 2014 B2
8816787 Jenkins et al. Aug 2014 B2
8828762 Chu et al. Sep 2014 B2
8834967 Afzali-Ardakani et al. Sep 2014 B2
8835686 Afzali-Ardakani et al. Sep 2014 B2
8852342 Dimitrakopoulos et al. Oct 2014 B2
8852985 Cai et al. Oct 2014 B2
8853034 Afzali-Ardakani et al. Oct 2014 B2
8859048 Afzali-Ardakani et al. Oct 2014 B2
8859439 Avouris et al. Oct 2014 B1
8877340 Chu et al. Nov 2014 B2
8878193 Avouris et al. Nov 2014 B2
8890116 Chen et al. Nov 2014 B2
8890121 Han et al. Nov 2014 B1
8895372 Guo et al. Nov 2014 B2
8895417 Afzali-Ardakani et al. Nov 2014 B2
8900538 Abou-Kandil et al. Dec 2014 B2
8900918 Avouris et al. Dec 2014 B2
8901680 Cai et al. Dec 2014 B2
8901689 Avouris et al. Dec 2014 B1
8911972 Chaisson et al. Dec 2014 B2
8912525 Afzali-Ardakani et al. Dec 2014 B2
8916451 Bayram et al. Dec 2014 B2
8927057 Bol et al. Jan 2015 B2
8932919 Farmer et al. Jan 2015 B2
8936763 Rothberg et al. Jan 2015 B2
8951727 Jaramillo-Botero et al. Feb 2015 B2
8952258 Plucinski et al. Feb 2015 B2
8957405 Adkisson et al. Feb 2015 B2
8957463 Afzali-Ardakani et al. Feb 2015 B2
8963215 Afzali-Ardakani et al. Feb 2015 B2
8968582 Franklin et al. Mar 2015 B2
8969090 Sun et al. Mar 2015 B2
8969115 Chen et al. Mar 2015 B2
8969118 Afzali-Ardakani et al. Mar 2015 B2
8975095 Han et al. Mar 2015 B2
8987740 Avouris et al. Mar 2015 B2
9000499 Franklin et al. Apr 2015 B2
9000594 Ott et al. Apr 2015 B2
9014989 McMillen et al. Apr 2015 B2
9017813 El-Ashry et al. Apr 2015 B2
9029841 Farmer et al. May 2015 B2
9040364 Farmer et al. May 2015 B2
9045796 Gunderson et al. Jun 2015 B2
9045842 Han et al. Jun 2015 B2
9051611 Christians et al. Jun 2015 B2
9059188 Dimitrakopoulos et al. Jun 2015 B1
9062389 Han et al. Jun 2015 B2
9064698 Khakifirooz et al. Jun 2015 B1
9064776 Lin et al. Jun 2015 B2
9064842 Bol et al. Jun 2015 B2
9068221 Merriman et al. Jun 2015 B2
9068936 Guo et al. Jun 2015 B2
9076873 Chen et al. Jul 2015 B2
9082856 Chen et al. Jul 2015 B2
9085802 Liu et al. Jul 2015 B2
9087691 Zhu et al. Jul 2015 B2
9091648 Afzali-Ardakani et al. Jul 2015 B2
9093507 Cohen et al. Jul 2015 B2
9093631 Davis Jul 2015 B2
9097658 Afzali-Ardakani et al. Aug 2015 B2
9099542 Franklin et al. Aug 2015 B2
9102118 Afzali-Ardakani et al. Aug 2015 B2
9102540 Afzali-Ardakani et al. Aug 2015 B2
9103776 Afzali-Ardakani et al. Aug 2015 B2
9105702 Franklin et al. Aug 2015 B2
9105853 Afzali-Ardakani et al. Aug 2015 B2
9123454 Franklin et al. Sep 2015 B2
9142471 Abou-Kandil et al. Sep 2015 B2
9145295 Peng Sep 2015 B2
9146209 Johnson et al. Sep 2015 B2
9150918 Turner et al. Oct 2015 B2
9157887 Guo et al. Oct 2015 B2
9162883 El-Ashry et al. Oct 2015 B2
9174413 Avouris et al. Nov 2015 B2
9174414 Avouris et al. Nov 2015 B2
9177688 Bol et al. Nov 2015 B2
9179579 Hada et al. Nov 2015 B2
9281305 Yang Mar 2016 B1
9618474 van Rooyen et al. Apr 2017 B2
20020164588 Eisenberg et al. Nov 2002 A1
20020194173 Bjornson et al. Dec 2002 A1
20030033279 Gibson et al. Feb 2003 A1
20030200033 Segal et al. Oct 2003 A1
20030224384 Sayood et al. Dec 2003 A1
20030228618 Levanon et al. Dec 2003 A1
20040072204 Shibuya Apr 2004 A1
20040110227 Levanon et al. Jun 2004 A1
20040142347 Stockwell et al. Jul 2004 A1
20040143571 Bjornson et al. Jul 2004 A1
20040152108 Keith et al. Aug 2004 A1
20040241730 Yakhini et al. Dec 2004 A1
20040248189 Bulaj et al. Dec 2004 A1
20050009771 Levanon et al. Jan 2005 A1
20050038609 Benner Feb 2005 A1
20050039123 Kuchinsky et al. Feb 2005 A1
20050107961 Uemura et al. May 2005 A1
20050131649 Larsen et al. Jun 2005 A1
20050188294 Kuchinsky et al. Aug 2005 A1
20050197783 Kuchinsky et al. Sep 2005 A1
20050240352 Liang Oct 2005 A1
20060016699 Kamahori et al. Jan 2006 A1
20060028471 Kincaid et al. Feb 2006 A1
20060064247 Yuan et al. Mar 2006 A1
20060100788 Carrino et al. May 2006 A1
20060106545 Balaji et al. May 2006 A1
20060141529 Koleske et al. Jun 2006 A1
20060275794 Carrino et al. Dec 2006 A1
20060294059 Chamberlain et al. Dec 2006 A1
20070063304 Matsumoto Mar 2007 A1
20070067108 Buhler et al. Mar 2007 A1
20070088510 Li et al. Apr 2007 A1
20070134692 Valmeekam et al. Jun 2007 A1
20070138463 Herlogsson et al. Jun 2007 A1
20070152335 Chun Jul 2007 A1
20070196816 Schwartz et al. Aug 2007 A1
20070232060 Niu Oct 2007 A1
20070259337 Hully et al. Nov 2007 A1
20070277036 Chamberlain et al. Nov 2007 A1
20080035494 Gomez et al. Feb 2008 A1
20080063566 Matsumoto Mar 2008 A1
20080086274 Chamberlain et al. Apr 2008 A1
20080104041 Bjornson et al. May 2008 A1
20080154567 Qiu et al. Jun 2008 A1
20080250016 Farrar Oct 2008 A1
20080274912 Johnson et al. Nov 2008 A1
20080283875 Mukasa Nov 2008 A1
20090008629 Matsumoto Jan 2009 A1
20090014757 Takulapalli Jan 2009 A1
20090119313 Pearce May 2009 A1
20090125248 Shams et al. May 2009 A1
20090153130 Shim et al. Jun 2009 A1
20090156431 Lok Jun 2009 A1
20090171647 Mannava et al. Jul 2009 A1
20090278556 Man et al. Nov 2009 A1
20090292665 Den Hartog Nov 2009 A1
20090325239 Lok Dec 2009 A1
20100025660 Jain et al. Feb 2010 A1
20100035254 Williams Feb 2010 A1
20100069263 Shendure et al. Mar 2010 A1
20100075309 Maxham et al. Mar 2010 A1
20100075327 Maxham et al. Mar 2010 A1
20100077267 Perego et al. Mar 2010 A1
20100082805 Orton et al. Apr 2010 A1
20100088040 Johnson, Jr. Apr 2010 A1
20100105202 Daamen Apr 2010 A1
20100121582 Pan et al. May 2010 A1
20100176463 Koizumi et al. Jul 2010 A1
20100227384 Vann Sep 2010 A1
20100228496 Leong et al. Sep 2010 A1
20100293167 Biasci et al. Nov 2010 A1
20100304989 Von Hoff et al. Dec 2010 A1
20100327847 Leiber et al. Dec 2010 A1
20110003301 Raymond et al. Jan 2011 A1
20110004413 Carnevali et al. Jan 2011 A1
20110042673 Yamabayashi Feb 2011 A1
20110098193 Kingsmore et al. Apr 2011 A1
20110121273 Jo May 2011 A1
20110177517 Rava et al. Jul 2011 A1
20110195406 Sorenson et al. Aug 2011 A1
20110201507 Rava et al. Aug 2011 A1
20110210314 Chung et al. Sep 2011 A1
20110212464 Hagmann et al. Sep 2011 A1
20110224087 Quake et al. Sep 2011 A1
20110227043 Guo et al. Sep 2011 A1
20110230358 Rava Sep 2011 A1
20110231446 Buhler et al. Sep 2011 A1
20110237444 Clancy et al. Sep 2011 A1
20110245085 Rava et al. Oct 2011 A1
20110252008 Chamberlain et al. Oct 2011 A1
20110257889 Klammer et al. Oct 2011 A1
20110270533 Zhang et al. Nov 2011 A1
20110281740 Beechem et al. Nov 2011 A1
20110281768 Travers et al. Nov 2011 A1
20110295514 Breu et al. Dec 2011 A1
20110295858 Ahn et al. Dec 2011 A1
20110295977 Shibuya Dec 2011 A1
20110296543 Chang et al. Dec 2011 A1
20120001615 Levine Jan 2012 A1
20120010085 Rava et al. Jan 2012 A1
20120011086 Zhang et al. Jan 2012 A1
20120021918 Bashir et al. Jan 2012 A1
20120046175 Rodesch et al. Feb 2012 A1
20120046877 Hyland et al. Feb 2012 A1
20120053845 Bruestle et al. Mar 2012 A1
20120089339 Ganeshalingam et al. Apr 2012 A1
20120094849 Rava et al. Apr 2012 A1
20120095697 Halpern et al. Apr 2012 A1
20120100548 Rava et al. Apr 2012 A1
20120102041 Park et al. Apr 2012 A1
20120109849 Chamberlain et al. May 2012 A1
20120110316 Chamberlain et al. May 2012 A1
20120116688 Mishra et al. May 2012 A1
20120149582 Rava et al. Jun 2012 A1
20120156677 Bitinaite et al. Jun 2012 A1
20120165203 Quake et al. Jun 2012 A1
20120197623 Homer Aug 2012 A1
20120203792 Zhang et al. Aug 2012 A1
20120208706 Downing et al. Aug 2012 A1
20120214172 Chen et al. Aug 2012 A1
20120214678 Rava et al. Aug 2012 A1
20120220053 Lee et al. Aug 2012 A1
20120221249 Lizardi et al. Aug 2012 A1
20120221432 Yuan et al. Aug 2012 A1
20120237928 Rava et al. Sep 2012 A1
20120264121 Rava et al. Oct 2012 A1
20120270739 Rava et al. Oct 2012 A1
20120271558 Hur et al. Oct 2012 A1
20120286244 Chiu et al. Nov 2012 A1
20120289408 Travers et al. Nov 2012 A1
20120289412 Seitz et al. Nov 2012 A1
20120295260 Pan et al. Nov 2012 A1
20120330559 Jiang et al. Dec 2012 A1
20120330566 Chaisson Dec 2012 A1
20130018599 Peng Jan 2013 A1
20130029852 Rava et al. Jan 2013 A1
20130034546 Rava et al. Feb 2013 A1
20130054151 Kermani et al. Feb 2013 A1
20130054508 Kermani et al. Feb 2013 A1
20130059740 Drmanac et al. Mar 2013 A1
20130085681 Deciu et al. Apr 2013 A1
20130091126 Krishnaswami et al. Apr 2013 A1
20130091176 Harris et al. Apr 2013 A1
20130096011 Rava et al. Apr 2013 A1
20130096841 Kermani et al. Apr 2013 A1
20130103320 Dzakula et al. Apr 2013 A1
20130124100 Drmanac et al. May 2013 A1
20130137588 Shendure et al. May 2013 A1
20130137605 Shendure et al. May 2013 A1
20130138355 Inglis et al. May 2013 A1
20130138358 Tang et al. May 2013 A1
20130140518 Jain et al. Jun 2013 A1
20130150253 Deciu et al. Jun 2013 A1
20130157870 Pushkarev et al. Jun 2013 A1
20130164859 Johnson et al. Jun 2013 A1
20130166221 Inglis et al. Jun 2013 A1
20130184161 Kingsmore et al. Jul 2013 A1
20130190211 Bustillo et al. Jul 2013 A1
20130091121 Bhola et al. Aug 2013 A1
20130194882 Ishii et al. Aug 2013 A1
20130204851 Bhola et al. Aug 2013 A1
20130211729 Sastry-Dent et al. Aug 2013 A1
20130230909 Pan et al. Sep 2013 A1
20130237432 Li et al. Sep 2013 A1
20130240378 Lee et al. Sep 2013 A1
20130245958 Forster Sep 2013 A1
20130251726 Mascola et al. Sep 2013 A1
20130261983 Dzakula et al. Oct 2013 A1
20130273543 Gudmundsson et al. Oct 2013 A1
20130288244 Deciu et al. Oct 2013 A1
20130288901 Kennedy et al. Oct 2013 A1
20130296175 Rafnar et al. Nov 2013 A1
20130297221 Johnson et al. Nov 2013 A1
20130304392 Deciu et al. Nov 2013 A1
20130307029 Xu et al. Nov 2013 A1
20130309666 Deciu et al. Nov 2013 A1
20130309678 Travers et al. Nov 2013 A1
20130310260 Kim et al. Nov 2013 A1
20130311106 White et al. Nov 2013 A1
20130316331 Isakov et al. Nov 2013 A1
20130316915 Halpern et al. Nov 2013 A1
20130316916 Flusberg et al. Nov 2013 A1
20130324417 Kennedy et al. Dec 2013 A1
20130324419 Seshagiri Dec 2013 A1
20130325360 Deciu et al. Dec 2013 A1
20130325666 Carrino et al. Dec 2013 A1
20130332081 Reese et al. Dec 2013 A1
20130338012 Sulem et al. Dec 2013 A1
20130338933 Deciu et al. Dec 2013 A1
20130338934 Asadi et al. Dec 2013 A1
20130345066 Brinza et al. Dec 2013 A1
20140024536 Richards et al. Jan 2014 A1
20140024541 Richards et al. Jan 2014 A1
20140024542 Richards et al. Jan 2014 A1
20140025312 Chin et al. Jan 2014 A1
20140031240 Behlke et al. Jan 2014 A1
20140033125 Meral Jan 2014 A1
20140034880 Blouin et al. Feb 2014 A1
20140038830 Srinivasan et al. Feb 2014 A1
20140045705 Bustamante et al. Feb 2014 A1
20140051154 Hyland et al. Feb 2014 A1
20140051588 Drmanac et al. Feb 2014 A9
20140053294 Gresshoff Feb 2014 A1
20140066317 Talasaz Mar 2014 A1
20140067830 Buhler et al. Mar 2014 A1
20140087961 Sulem et al. Mar 2014 A1
20140100792 Deciu et al. Apr 2014 A1
20140114582 Mittelman et al. Apr 2014 A1
20140121116 Richards et al. May 2014 A1
20140122509 Pantaleoni et al. May 2014 A1
20140129201 Kennedy et al. May 2014 A1
20140134629 Turner et al. May 2014 A1
20140148346 Spormann et al. May 2014 A1
20140149049 Chen et al. May 2014 A1
20140152291 Afzali-Ardakani et al. Jun 2014 A1
20140155298 Von Hoff et al. Jun 2014 A1
20140156199 Von Hoff et al. Jun 2014 A1
20140162278 Richards et al. Jun 2014 A1
20140163900 Erlich et al. Jun 2014 A1
20140166487 Lieber et al. Jun 2014 A1
20140172319 Von Hoff et al. Jun 2014 A1
20140173606 Pantaleoni Jun 2014 A1
20140193938 Fife Jul 2014 A1
20140200166 Van Rooyen et al. Jul 2014 A1
20140209982 Putnam et al. Jul 2014 A1
20140236490 McMillen et al. Aug 2014 A1
20140248692 Lagace et al. Sep 2014 A1
20140249052 Mehmet et al. Sep 2014 A1
20140260547 Balandin Sep 2014 A1
20140264467 Cheng et al. Sep 2014 A1
20140264469 Fife et al. Sep 2014 A1
20140274774 Li et al. Sep 2014 A1
20140297196 Olson Oct 2014 A1
20140309944 McMillen et al. Oct 2014 A1
20140315199 Rhodes et al. Oct 2014 A1
20140363808 Gu et al. Dec 2014 A1
20140371109 McMillen et al. Dec 2014 A1
20140371110 Van Rooyen et al. Dec 2014 A1
20150065353 Turner et al. Mar 2015 A1
20150069329 Jeon et al. Mar 2015 A1
20150087534 Gormley et al. Mar 2015 A1
20150101931 Garaj et al. Apr 2015 A1
20150111759 Ju et al. Apr 2015 A1
20150123080 Yamaguchi May 2015 A1
20150137078 Guo et al. May 2015 A1
20150159196 Travers et al. Jun 2015 A1
20150159212 Pantoja et al. Jun 2015 A1
20150160159 Afzali-Ardakani et al. Jun 2015 A1
20150176071 Fisher et al. Jun 2015 A1
20150211054 Kostem et al. Jul 2015 A1
20150218630 Sun et al. Aug 2015 A1
20150225785 Zhao et al. Aug 2015 A1
20150232929 Stephens et al. Aug 2015 A1
20150233864 Shen et al. Aug 2015 A1
20150239947 Brinkmann et al. Aug 2015 A1
20150243917 Kim et al. Aug 2015 A1
20150259743 Urgess et al. Sep 2015 A1
20150302143 Ma et al. Oct 2015 A1
20150302144 Chin et al. Oct 2015 A1
20150307936 Goldsmith Oct 2015 A1
20150307947 Basu et al. Oct 2015 A1
20150308977 Saito et al. Oct 2015 A1
20150339437 McMillen et al. Nov 2015 A1
20150368638 Steemers et al. Dec 2015 A1
20160004298 Mazed et al. Jan 2016 A1
20160122792 Peterson et al. May 2016 A1
20160171153 Van Rooyen et al. Jun 2016 A1
20160180019 Van Rooyen et al. Jun 2016 A1
20160231251 Ou et al. Aug 2016 A1
20160265047 van Rooyen et al. Sep 2016 A1
20170018626 Hoffman et al. Jan 2017 A1
20170053908 Hoffman Feb 2017 A1
20170059514 Hoffman Mar 2017 A1
20170102358 Hoffman Apr 2017 A1
20170218442 van Rooyen et al. Aug 2017 A1
Foreign Referenced Citations (139)
Number Date Country
102703594 Oct 2012 CN
202854094 Apr 2013 CN
103293209 Sep 2013 CN
104237352 Dec 2014 CN
19813317 Sep 1999 DE
2163646 Mar 2010 EP
2334802 Jun 2011 EP
2535429 Dec 2012 EP
3 235 010 Oct 2017 EP
2004085392 Mar 2004 JP
2010172290 Aug 2010 JP
WO-99049403 Sep 1999 WO
WO-00045322 Aug 2000 WO
WO-0113432 Feb 2001 WO
WO-02090978 Nov 2002 WO
WO-03046220 Jun 2003 WO
WO-2004029298 Apr 2004 WO
WO-2004090100 Oct 2004 WO
WO-2004104161 Dec 2004 WO
WO-2005026925 Mar 2005 WO
WO-2005029059 Mar 2005 WO
WO-2005048134 May 2005 WO
WO-2005090961 Sep 2005 WO
WO-2005113812 Dec 2005 WO
WO-2006015084 Feb 2006 WO
WO-2006019892 Feb 2006 WO
WO-2006096324 Sep 2006 WO
WO-2007064758 Jun 2007 WO
WO-2007076726 Jul 2007 WO
WO-2008022036 Feb 2008 WO
WO-2008098014 Aug 2008 WO
WO-2008127213 Oct 2008 WO
WO-2008143679 Nov 2008 WO
WO-2008156773 Dec 2008 WO
WO-2009035647 Mar 2009 WO
WO-2009120372 Oct 2009 WO
WO-2009143212 Nov 2009 WO
WO-2010003316 Jan 2010 WO
WO-2010027497 Mar 2010 WO
WO-2010036287 Apr 2010 WO
WO-2010036311 Apr 2010 WO
WO-2010051773 May 2010 WO
WO-2010072382 Jul 2010 WO
WO-2010093465 Aug 2010 WO
WO-2010127045 Nov 2010 WO
WO-2010129019 Nov 2010 WO
WO-2010129301 Nov 2010 WO
WO-2010132814 Nov 2010 WO
WO-2011025819 Mar 2011 WO
WO-2011050341 Apr 2011 WO
WO-2011056688 May 2011 WO
WO-2011063210 May 2011 WO
WO-2011071923 Jun 2011 WO
WO-2011082178 Jul 2011 WO
WO-2011090556 Jul 2011 WO
WO-2011090557 Jul 2011 WO
WO-2011090558 Jul 2011 WO
WO-2011090559 Jul 2011 WO
WO-2011091046 Jul 2011 WO
WO-2011091063 Jul 2011 WO
WO-2011095501 Aug 2011 WO
WO-2011137368 Nov 2011 WO
WO-2011139797 Nov 2011 WO
WO-2011143525 Nov 2011 WO
WO-2011145954 Nov 2011 WO
WO-2011145955 Nov 2011 WO
WO-2012006291 Jan 2012 WO
WO-2012029080 Mar 2012 WO
WO-2012051346 Apr 2012 WO
WO-2012058459 May 2012 WO
WO-2012065228 May 2012 WO
WO-2012066582 May 2012 WO
WO-2012085948 Jun 2012 WO
WO-2012092336 Jul 2012 WO
WO-2012092426 Jul 2012 WO
WO-2012095872 Jul 2012 WO
WO-2012101643 Aug 2012 WO
WO-2012123972 Sep 2012 WO
WO-2012142334 Oct 2012 WO
WO-2012142531 Oct 2012 WO
WO-2012168803 Dec 2012 WO
WO-2012168815 Dec 2012 WO
WO-2012170715 Dec 2012 WO
WO-2012172575 Dec 2012 WO
WO-2012177774 Dec 2012 WO
WO-2012177792 Dec 2012 WO
WO-2013043909 Mar 2013 WO
WO-2013052907 Apr 2013 WO
WO-2013052913 Apr 2013 WO
WO-2013055817 Apr 2013 WO
WO-2013058907 Apr 2013 WO
WO-2013062856 May 2013 WO
WO-2013065072 May 2013 WO
WO-2013067167 May 2013 WO
WO-2013080227 Jun 2013 WO
WO-2013088457 Jun 2013 WO
WO-2013109935 Jul 2013 WO
WO-2013109981 Jul 2013 WO
WO-2013119770 Aug 2013 WO
WO-2013123330 Aug 2013 WO
2013128371 Sep 2013 WO
WO-2013148400 Oct 2013 WO
WO-2013166517 Nov 2013 WO
WO-2013177086 Nov 2013 WO
WO-2013177581 Nov 2013 WO
WO-2013184643 Dec 2013 WO
WO-2013192562 Dec 2013 WO
WO-2014008447 Jan 2014 WO
WO-2014012051 Jan 2014 WO
WO-2014014497 Jan 2014 WO
WO-2014014498 Jan 2014 WO
WO-2014014950 Jan 2014 WO
WO-2014015084 Jan 2014 WO
WO-2014015319 Jan 2014 WO
WO-2014018093 Jan 2014 WO
WO-2014024041 Feb 2014 WO
WO-2014024598 Feb 2014 WO
WO-2014026168 Feb 2014 WO
WO-2014036488 Mar 2014 WO
WO-2014039556 Mar 2014 WO
WO-2014041380 Mar 2014 WO
2014060305 Apr 2014 WO
WO-2014052909 Apr 2014 WO
WO-2014055774 Apr 2014 WO
2014074246 May 2014 WO
WO-2014071070 May 2014 WO
WO-2014071279 May 2014 WO
WO-2014078739 May 2014 WO
WO-2014089241 Jun 2014 WO
WO-2014112199 Jul 2014 WO
WO-2014142850 Sep 2014 WO
WO-2014153188 Sep 2014 WO
WO-2014166535 Oct 2014 WO
WO-2014171969 Oct 2014 WO
WO-2014172046 Oct 2014 WO
WO-2014176524 Oct 2014 WO
WO-2015033229 Mar 2015 WO
WO-2015123444 Aug 2015 WO
WO-2016205253 Dec 2016 WO
Non-Patent Literature Citations (23)
Entry
Definition of “Well”, http://www.merriam-webster.com (2016).
International Search Report for PCT Application No. PCT/US2015/064848, dated Mar. 31, 2016.
Basu et al., Recent Advances in Carbon Nanotubes Based Biosensors, Sensors, 8:1-x manuscripts, downloaded from: http://www.mdpi.org/sensors/accepted/sensors-util-24-21-malhorta-in-PRE-PUBLISHED-VERSION-0422.pdf (Jan. 31, 2008).
Cooper et al., Experimental Review of Graphene, ISRN Condensed Matter Physics 2012: Art. ID 501686, 56 pages. (2012).
DeVolder et al., Carbon Nanotubes: Present and Future Commercial Applications, Science, 339: 535-539 (Feb. 1, 2013).
Fakih et al., Large area graphene ion sensitive field effect transistors with tantalum pentoxide sensing layers for pH measurement at the Nernstian limit, Applied Physics Letters 105: 083101 (Aug. 25, 2014).
Gao et al., The new age of carbon nanotubes: An updated review of functionalized carbon nanotubes in electrochemical sensors, Nanoscale 4:1948 (2012).
Green et al., Interactions of DNA with graphene and sensing applications of graphene field-effect transistor devices: A review, Analytica Chimica Acta 853:127-142 (2015).
Kim, Lecture Notes, 2.76/2.760 Multiscale Systems Design & Manufacturing, downloaded from: http://ocw.mit.edu/courses/mechanical-engineering/2-76-multi-scale-system-design-fall-2004/lecture-notes/lecture_15.pdf (Fall 2004).
Park et al., High-density integration of carbon nanotubes via chemical self-assembly, Nature Nanotechnology 7:787-791 (2012).
Schwierz, Frank; Graphene Transistors, Nature Nanotechnology 5:487-496 (May 30, 2010).
Tulevski et al., Toward High-Performance Digital Logic Technology with Carbon Nanotubes, ACS Nano 8(9):8730-8745 (Aug. 21, 2014).
Zhan et al., Graphene Field-Effect Transistor and Its Application for Electronic Sensing, Small 10(20):4042-4065 (Aug. 29, 2014).
Cheng, Zengguang et al. “Sensitivity Limits and Scaling of Bioelectronic Graphene Transducers.”, Nano Letters, (2013), pp. 2902-2907, 13(6), ACS Publications.
Cheng, Zengguang et al. “Supporting Information for: Sensitivity Limits and Scaling of Bioelectronic Graphene Transducers.”, (2013), 26 pages, pubs.acs.org. [retrieved from the Internet on Nov. 7, 2017].
Cheng, Zengguang et al. “Suspended Graphene Sensors with Improved Signal and Reduced Noise.” Nano Letters, (2010), pp. 1864-1868, 10(5), pubs.acs.org.
Kim, Kihyun et al. “Electrical and pH Sensing Characteristics of Si Nanowire-Based Suspended FET Biosensors.” Proceedings of the 14th IEEE, International Conference on Nanotechnology, IEEE, (Aug. 18-21, 2014), pp. 768-771.
Kim, Kihyun et al. “Suspended honeycomb nanowire ISFETs for improved stiction-free performance.” Nanotechnology,(2014), pp. 345-501 (7 pages), 25(34), IOP Publishing, Bristol, GB.
Wang, Bei et al. “Oxide-on-graphene field effect bio-ready sensors.” Nano Research, (2014), 7(9):pp. 1263-1270. Tsinghua University Press, CN.
Xu et al. “Electrophoretic and field-effect graphene for all-electrical DNA array technology.” Nature Communications, (2014) 5:4866. 9 pages.
Liu, Song and Xuefeng Guo, “Carbon nanomaterials field-effect-transistor-based biosensors.” NPG Asia Materials (2012), pp. 1-10, 4, e23; doi: 10.1038/sm.2012.42: published online Aug. 17, 2012.
Baraket, Mira et al. (2008) “Aminated graphene for DNA attachment produced via plasma functionalization”, Applied Physics Letters, A I P Publishing LLC, US, vol. 100, No. 23, Jun. 4, 2012 (Jun. 4, 2012) pp. 233123-233123-4, XP012156487, ISSN: 0003-6951, DOI: 10.1063/1.4711771 [retrieved on Jun. 8, 2012].
Schwierz, Frank, J. Pezoldt and R. Granzner, “Two-dimensional materials and their prospect in transistor electonics.” Nanoscale, 2015, 7, pp. 8261-8283.
Related Publications (1)
Number Date Country
20160178569 A1 Jun 2016 US
Provisional Applications (4)
Number Date Country
62206228 Aug 2015 US
62199987 Aug 2015 US
62130594 Mar 2015 US
62094016 Dec 2014 US